Treatment of patients with Graves' ophthalmopathy by immunosuppressive agent and 99Tc-MDP / 生物医学工程学杂志
Journal of Biomedical Engineering
; (6): 300-323, 2002.
Article
in Chinese
| WPRIM (Western Pacific)
| ID: wpr-263604
Responsible library:
WPRO
ABSTRACT
The purpose of this study was to evaluate the efficacy of immunosuppressive agents, 99Tc-MDP and both of them in treating patients with Graves' ophthalmopathy(GO). The efficacy was evaluated by randomized controlled trial involving a total of 66 patients. In 22 patients treated with immunosuppressive agents, the general efficacy rate was 19/22, the incidence rate of serious side-effect was 8/22. In 20 patients treated with 99Tc-MDP, the general efficacy rate was 17/20, the incidence rate of serious side-effect was 2/20. In 24 patients treated with immunosuppressive agents and 99Tc-MDP, the general efficacy rate was 22/24, the incidence rate of serious side-effect was 2/24. The results suggested that in the treatment of Graves' ophthalmopathy, when satisfactory efficacy was obtained, the serious side-effect and 'rebound' of symptom could be avoided by using immunosuppressive agents in combination with 99Tc-MDP.
Full text:
Available
Database:
WPRIM (Western Pacific)
Main subject:
Technetium Tc 99m Medronate
/
Therapeutic Uses
/
Drug Therapy
/
Graves Ophthalmopathy
/
Immunosuppressive Agents
Type of study:
Controlled clinical trial
Limits:
Humans
Language:
Chinese
Journal:
Journal of Biomedical Engineering
Year:
2002
Document type:
Article